久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA approves AbbVie’s Orilissa for endometriosis pain pharmaceutical-technology
    July 26, 2018
    The US Food and Drug Administration (FDA) has approved AbbVie and Neurocrine Biosciences’ drug Orilissa (elagolix) for women with moderate to severe endometriosis pain.
  • US approves AbbVie/Neurocrine’s uterine pain drug pharmatimes
    July 26, 2018
    AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service